Additional file 3: of EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC

Figure S3. JQ1 resulted in a greater reduction of tumor growth than sorafenib in vivo. (a) BEL-7402 and 97-L cells (5 × 106 each) were injected into the flanks of CB17/SCID mice. After the subcutaneous tumors reached a size of 10 cm3, mice were randomly treated with vehicle, JQ1 or sorafenib at 50 mg/kg every 2 days. Tumor images is shown. (b) Analysis of apoptosis in 97-L tumor xenografts by IHC staining. Tumors from mice treated with vehicle, JQ1, or sorafenib were stained with H&E, MYC, and TUNEL. Representative immunohistochemistry images were shown. (c) Immunoblot analysis of tumor lysates treated with vehicle, JQ1 or sorafenib, using the indicated antibodies. (TIF 1170 kb